Alfameda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,128,989 | 628,475 | 1,240,435 | 883,188 | 842,673 | 1,765,551 | 1,190,434 | 1,822,100 |
| Profit before tax | 105,691 | 11,096 | 148,715 | 145,762 | 3,355 | 67,986 | 3,382 | -19,345 |
| Net profit | 87,956 | 9,307 | 125,700 | 123,628 | 3,355 | 64,689 | 2,890 | -22,163 |
| Equity | 463,853 | 364,796 | 493,335 | 613,812 | 615,133 | 682,645 | 568,887 | 540,784 |
| Liabilities | 332,296 | 331,726 | 261,593 | 354,906 | 336,053 | 773,750 | 403,455 | 664,360 |
| Non-current assets | 133,095 | 122,549 | 98,018 | 77,671 | 226,668 | 300,522 | 324,053 | 228,347 |
| Current assets | 661,641 | 549,116 | 651,932 | 886,270 | 737,797 | 1,193,227 | 663,361 | 964,487 |
| Total assets | 794,736 | 671,665 | 749,950 | 963,941 | 964,465 | 1,493,749 | 987,414 | 1,192,834 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 126,856 | 302,455 | 146,500 |
| Social insurance contributions | - | - | - | - | - | 42,907 | 46,701 | 50,889 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +43.4% | -44.3% | +97.4% | -28.8% | -4.6% | +109.5% | -32.6% | +53.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 11.1% | 1.4% | 16.8% | 12.8% | 0.3% | 4.3% | 0.3% | -1.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 19.0% | 2.6% | 25.5% | 20.1% | 0.5% | 9.5% | 0.5% | -4.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 7.8% | 1.5% | 10.1% | 14.0% | 0.4% | 3.7% | 0.2% | -1.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 9.4% | 1.8% | 12.0% | 16.5% | 0.4% | 3.9% | 0.3% | -1.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.7 | 0.9 | 0.5 | 0.6 | 0.5 | 1.1 | 0.7 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 98,173 | 52,373 | 99,235 | 73,599 | 75,463 | 147,129 | 99,896 | 163,173 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Alfameda - Social security debts
The company had no debts to Sodra
Alfameda - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-08-15 | 2025-08-18 | 687.3 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Alfameda, UAB (company code 235224120) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated €1.82M in revenue, up 53.1% year on year and 3.2% higher than two years earlier. Despite the stronger top-line performance, profitability weakened and the year ended with a net loss of €22.2K, compared with a small profit of €2.9K in 2024 and €64.7K in 2023. The 2025 profit margin was -1.2%, reflecting the return to losses after a near break-even 2024. At year-end 2025, total assets stood at €1.19M, with equity of €540.8K and liabilities of €664.4K. The equity ratio was 45.3%, while debt-to-equity was 1.23. Asset turnover reached 1.53x, indicating relatively efficient use of assets in generating revenue. Revenue per employee was €165.6K, while profit per employee was -€2.0K, consistent with the negative result for the latest financial year.